Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470203) titled 'Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer' on March 9.
Study Type: Observational
Primary Sponsor: Peking University Cancer Hospital & Institute
Condition:
HER2-positive Breast Cancer
Intervention:
Drug: Pyrotinib
Drug: Trastuzuma
Drug: Pertuzumab
Recruitment Status: Not recruiting
Date of First Enrollment: March 31, 2026
Target Sample Size: 42
To know more, visit https://clinicaltrials.gov/study/NCT07470203
Published by HT Digital Content Services with permission from Health Daily Digest....